Skip to main content

Table 3 Drug survival at one, two, and three years by diagnosis

From: Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER

  Drug survival [95% confidence interval]
Diagnosis One year Two years Three years
Rheumatoid arthritis 0.83 [0.81–0.84] 0.72 [0.71–0.74] 0.65 [0.63–0.67]
All spondylarthritis 0.88 [0.86–0.90]* 0.82 [0.79–0.84]* 0.74 [0.71–0.78]*
   Ankylosing spondylitis 0.88 [0.85–0.91] 0.82 [0.78–0.86] 0.76 [0.70–0.80]
   Psoriatic arthritis 0.88 [0.84–0.90] 0.81 [0.77–0.84] 0.73 [0.67–0.78]
   Undifferentiated spondylarthritis 0.88 [0.81–0.91] 0.83 [0.76–0.88] 0.72 [0.60–0.80]
   Crohn's related spondylarthritis 0.90 [0.79–0.95] 0.86 [0.73–0.93] 0.82 [0.69–0.91]
   Other spondylarthritis 0.79 [0.53–0.92] 0.61 [0.31–0.81] 0.61 [0.31–0.81]
  1. *p of the difference versus survival at the same time in rheumatoid arthritis < 0.001 (by log-rank test).